Sapan Ghai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Just read through the research note by HCW and it truly signifies a monster in the making.
they give a $1.25bn valuation of TILs EXCLUDING all contribution from foralumab in areas beyond Crohn's disease, milciclib in cancers beyond HCC for any indication and Accustem Sciences (formerly StemPrintER).
Boooom.
Every Tils share holder will get a 1;1 share in Accustem sciences which should ipo at circa $280M IN Q4 (cut off date in 24 trading days) - This was the main reason i invested a few months ago. CE mark to follow and FDA approval after that which will be inflection points for the new company. I will hold onto my Accustem shares.
Now the interesting part, Tiziana to conduct a clinical Study with nasally administered Foralumab, a Fully Human Anti-CD3 monoclonal antibody, for treatment of COVID-19 patients in Brazil - Ask yourselves, why are the company fast tracking a covid trial which was due to start in Q1 2020?
The key part for me is the combination of Forulamab with other anti viral drugs. Many well respected scientists and Dr's have come on record to state that they believe the 'cure' for Covid will be through a ****tail of a monoclonal antibody in combination with other antivirals (Dr Anthony Fauci and Dr Bruce Patterson to name a few). A potential data readout before Christmas could fuel a huge rerate in the SP. (SNG 10X bagged on their results).
The Company has developed a robust formulation for delivery of Foralumab using a nasal spray device and has successfully completed a Phase 1 clinical trial demonstrating that the treatment was well-tolerated up to 250 microg/day and that it stimulated Tregs (https://www.tizianalifesciences.com/news-item?s=2018-11-28-tiziana-announces-initiation-of-phase-1-clinical-trial-with-nasal-administration-of-foralumab-a-fully-human-anti-cluster-definition-3-monoclonal-antibody-anti-cd3-mab-in-healthy-volunteers). Thus, we believe the clinical strategy with nasal administration of Foralumab either alone or in combination with dexamethasone to treat COVID-19 patients is highly innovative and scientifically very sound.
We can be highly hopeful that the trial will be successful and then that will create a huge re rating. I really cant see anything that has more potential over the next 12 weeks that this share.
The short will close as we get nearer to the Accustem spin off date, the bears have made money shorting the stock but would be foolish to keep the short open as the cutoff date nears.
The bulls continue to get torpedoed but the thesis remains afloat. Those who have weathered the storm and topped up over the last few weeks will be well rewarded over the next few months
Count your lucky stars that you found this gem of a company in its infancy!